Invivyd Revises COVID Antibody Data Timing As It Pursues Accelerated FDA Approval

PEMGARDA sales rose 18%, but its emergency authorization is due to end in mid-2027.

Share
Invivyd Revises COVID Antibody Data Timing As It Pursues Accelerated FDA Approval

Invivyd, which sells and develops antibody medicines for COVID-19, expects interim trial data imminently after revising the timing, it said in Monday's SEC filing and accompanying earnings release. The results would underpin its planned accelerated FDA approval application for VYD2311, a potential successor to PEMGARDA, whose emergency authorization is due to end in mid-2027.

An Approval Bid Built On Antibodies

Invivyd attributed the timing update to discussions with the FDA about refining VYD2311's accelerated approval approach and extending that approach to future antibody candidates, including its measles program.

The planned interim analysis will measure virus-neutralizing antibody responses, how the medicine behaves in the body, immune reactions and safety. Invivyd intends to keep symptomatic COVID case results blinded while using the interim measurements to support its application.

The late-stage prevention study, DECLARATION, has approximately 2,400 participants, including adults and adolescents with and without risk factors for severe COVID. It compares muscle injections given once or monthly with placebo. The company plans to continue collecting confirmed symptomatic infections; positive clinical results would provide evidence for conversion to traditional approval.

September's positive safety results came from LIBERTY, a separate trial comparing VYD2311 with an mRNA COVID vaccine. Invivyd said the candidate met the study's main and secondary goals, with superior safety and tolerability. Giving the antibody alongside the vaccine did not interfere with vaccine-induced neutralizing antibody responses.

PEMGARDA Grows Before Authorization Ends

PEMGARDA generated $15.4 million in third-quarter sales, up 18% from $13.1 million a year earlier. Invivyd attributed the increase primarily to greater patient demand.

The medicine has emergency authorization to prevent COVID in certain adults and adolescents with moderately to severely weakened immune systems who are unlikely to respond adequately to vaccination. Invivyd sells it through its own sales force to practitioners and institutions specializing in blood disorders, cancer, rheumatology and transplants.

In July, Invivyd announced advance notice that PEMGARDA's emergency authorization would terminate. The underlying emergency declaration is scheduled to end June 29, 2027. VYD2311's planned approval application is therefore part of the company's effort to develop another COVID prevention medicine.

Research spending rose to $18.7 million from $8.0 million a year earlier, mainly because of contract research for DECLARATION and LIBERTY, Invivyd said. Selling and administrative expenses increased to $30.3 million from $15.0 million, which the company attributed chiefly to staffing, communications and commercial costs.

The quarterly loss widened to $33.5 million from $10.5 million; loss per share increased to $0.10 from $0.06. Cash and equivalents totaled $126.4 million at the third quarter's end.

Chief Financial Officer Bill Duke said recent clinical-program spending was behind the company and that it looks forward to "a new posture of increased operating efficiency" while advancing VYD2311.

More Trials, Then Commercial Plans

Invivyd and the SPEAR Study Group, researchers assessing antibody therapy, announced the start of a mid-stage trial in October. That study evaluates VYD2311 in adults aged 18–65 with Long COVID or Post-Vaccination Syndrome, comparing three doses with placebo over 90 days.

The company is also scaling production of VMS063, its investigational measles antibody, toward clinical development in 2027. Laboratory testing showed antiviral activity against contemporary measles variants, according to Invivyd.

Invivyd plans a medical and commercial investor event in the first half of 2027 to outline VYD2311 commercialization plans.

Sources